Abstract
An “individual with a disability” has a physical impairment or record of such an impairment that substantially limits a “major life activity.” Today, “person with a disability” is a more widely used term than “handicapped” as this phrasing reflects a positive approach by putting people first, not the disability. The disability term is used to refer an individual functioning including motor, sensory, cognitive, intellectual impairment, mental illness, and various types of chronic diseases (Oliver 1995; Crow 2008).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Al-Araji AH, Oger J (2005) Reappraisal of Lhermitte’s sign in multiple sclerosis. Mult Scler J 11(4):398–402
Bax M et al (2005) Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol 47(8):571–576
Betarbet R et al (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3(12):1301
Bhattacharyya KB (2016) The story of George Huntington and his disease. Ann Indian Acad Neurol 19(1):25
Bitsch A et al (2000) Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain 123(6):1174–1183
Chandra V et al (2006) Neurological disorders. In: Disease control priorities. World Bank, Washington, DC, p 21
Cho HJ et al (2012) MicroRNA-205 regulates the expression of Parkinson’s disease-related leucine-rich repeat kinase 2 protein. Hum Mol Genet 22(3):608–620
Clifford DB, Trotter JL (1984) Pain in multiple sclerosis. Arch Neurol 41(12):1270–1272
Corti O, Lesage S, Brice A (2011) What genetics tells us about the causes and mechanisms of Parkinson’s disease. Physiol Rev 91(4):1161–1218
Crow KL (2008) Four types of disabilities: their impact on online learning. TechTrends 52(1):51–55
Ebers GC (2008) Environmental factors and multiple sclerosis. Lancet Neurol 7(3):268–277
Focke NK et al (2011) Differentiation of typical and atypical Parkinson syndromes by quantitative MR imaging. Am J Neuroradiol 32(11):2087–2092
Folstein SE, Brandt J, Folstein MF (1990) Huntington’s disease. Oxford University Press, New York
Freeman JM, Nelson KB (1988) Intrapartum asphyxia and cerebral palsy. Pediatrics 82(2):240–249
Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis—the plaque and its pathogenesis. N Engl J Med 354(9):942–955
Geurts JJ, Barkhof F (2008) Grey matter pathology in multiple sclerosis. Lancet Neurol 7(9):841–851
Goetz CG (2011) The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med 1(1):a008862
Goodin DS et al (2002) Disease modifying therapies in multiple sclerosis. Neurology 58(2):169–178
Guehl D et al (1999) Trichloroethylene and parkinsonism: a human and experimental observation. Eur J Neurol 6(5):609–611
Hannan AJ (2004) Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington’s disease. Acta Biochim Pol Engl Ed 51:415–430
Indaco A et al (1994) Chronic and acute pain syndromes in patients with multiple sclerosis. Acta Neurol 16(3):97
Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368–376
Jimenez-Sanchez M et al (2016) Huntington’s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med 7:a024240
Johnston MV, Hagberg H (2007) Sex and the pathogenesis of cerebral palsy. Dev Med Child Neurol 49(1):74–78
Jones MW et al (2007) Cerebral palsy: introduction and diagnosis (part I). J Pediatr Health Care 21(3):146–152
Kala SV, Jadhav AL (1995) Region-specific alterations in dopamine and serotonin metabolism in brains of rats exposed to low levels of lead. Neurotoxicology 16(2):297–308
Li S-H, Li X-J (2004) Huntingtin–protein interactions and the pathogenesis of Huntington’s disease. Trends Genet 20(3):146–154
Lim SY, Lang AE (2010) The nonmotor symptoms of Parkinson’s disease—an overview. Mov Disord 25(S1):S123–S130
Louis ED, Frucht SJ (2007) Prevalence of essential tremor in patients with Parkinson’s disease vs. Parkinson-plus syndromes. Mov Disord 22(10):1402–1407
Love S, Coakham HB (2001) Trigeminal neuralgia: pathology and pathogenesis. Brain 124(12):2347–2360
Marchand S (2008) The physiology of pain mechanisms: from the periphery to the brain. Rheum Dis Clin N Am 34(2):285–309
McPhee SJ, Hammer GD (1995) Pathophysiology of disease: an introduction to clinical medicine. Lange Medical Books, New York
Merskey H (1991) The definition of pain. Eur Psychiatry 6(4):153–159
Milo R, Kahana E (2010) Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 9(5):A387–A394
Minear W (1956) A classification of cerebral palsy. Pediatrics 18(5):841–852
Mo C, Hannan AJ, Renoir T (2015) Environmental factors as modulators of neurodegeneration: insights from gene–environment interactions in Huntington’s disease. Neurosci Biobehav Rev 52:178–192
Mohan H (2005) Textbook of pathology. Jaypee Brothers Medical Publishers, New Delhi.
Moulin DE, Foley KM, Ebers GC (1988) Pain syndromes in multiple sclerosis. Neurology 38(12):1830–1830
Navarro-Yepes J et al (2014) Antioxidant gene therapy against neuronal cell death. Pharmacol Ther 142(2):206–230
Nelson KB, Willoughby RE (2000) Infection, inflammation and the risk of cerebral palsy. Curr Opin Neurol 13(2):133–139
O’connor AB et al (2008) Pain associated with multiple sclerosis: systematic review and proposed classification. Pain 137(1):96–111
Oliver M (1995) Understanding disability: from theory to practice. Macmillan International Higher Education, Basingstoke
Orrell RW (2005) Multiple sclerosis: the history of a disease. Demos Medical Publishing, New York
Pahwa R, Lyons KE (2013) Handbook of Parkinson’s disease. CRC Press, Boca Raton
Panteliadis C, Panteliadis P, Vassilyadi F (2013) Hallmarks in the history of cerebral palsy: from antiquity to mid-20th century. Brain and Development 35(4):285–292
Pavlou MAS, Outeiro TF (2017) Epigenetics in Parkinson’s disease. In: Neuroepigenomics in aging and disease. Springer, Cham, pp 363–390
Perlman JM (1997) Intrapartum hypoxic-ischemic cerebral injury and subsequent cerebral palsy: medicolegal issues. Pediatrics 99(6):851–859
Popescu BFG, Pirko I, Lucchinetti CF (2013) Pathology of multiple sclerosis: where do we stand? Continuum Lifelong Learn Neurol 19(4 Multiple Sclerosis):901
Purkerson-Parker S, McDaniel KL, Moser VC (2001) Dopamine transporter binding in the rat striatum is increased by gestational, perinatal, and adolescent exposure to heptachlor. Toxicol Sci 64(2):216–223
Rappold PM et al (2011) Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. Proc Natl Acad Sci 108(51):20766–20771
Raymond LA et al (2011) Pathophysiology of Huntington’s disease: time-dependent alterations in synaptic and receptor function. Neuroscience 198:252–273
Reddihough DS, Collins KJ (2003) The epidemiology and causes of cerebral palsy. Aust J Physiother 49(1):7–12
Reid S et al (2006) Factor V Leiden mutation: a contributory factor for cerebral palsy? Dev Med Child Neurol 48(1):14–19
Reiner A et al (1988) Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci 85(15):5733–5737
Rosenbaum P et al (2007) A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl 109(Suppl 109):8–14
Sankar C, Mundkur N (2005) Cerebral palsy-definition, classification, etiology and early diagnosis. Indian J Pediatr 72(10):865–868
Smith KJ, McDonald W (1999) The pathophysiology of multiple sclerosis⋮ the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond Ser B Biol Sci 354(1390):1649–1673
Solaro C, Trabucco E, Uccelli MM (2013) Pain and multiple sclerosis: pathophysiology and treatment. Curr Neurol Neurosci Rep 13(1):320
Steffan JS et al (2004) SUMO modification of huntingtin and Huntington’s disease pathology. Science 304(5667):100–104
Steiner I, Nisipianu P, Wirguin I (2001) Infection and the etiology and pathogenesis of multiple sclerosis. Curr Neurol Neurosci Rep 1(3):271–276
Torfs CP et al (1990) Prenatal and perinatal factors in the etiology of cerebral palsy. J Pediatr 116(4):615–619
Tselis A (2011) Evidence for viral etiology of multiple sclerosis. In: Seminars in neurology. Thieme Medical Publishers, Inc., New York
Vale TC, Cardoso F (2015) Chorea: a journey through history. Tremor Other Hyperkinet Mov 5:pii: tre-5-296
van Dellen A, Hannan AJ (2004) Genetic and environmental factors in the pathogenesis of Huntington’s disease. Neurogenetics 5(1):9–17
Verina T et al (2011) Manganese exposure induces microglia activation and dystrophy in the substantia nigra of non-human primates. Neurotoxicology 32(2):215–226
Vonsattel J-P et al (1985) Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44(6):559–577
Wacker M, Holick MF (2013) Sunlight and vitamin D: a global perspective for health. Derm Endocrinol 5(1):51–108
Wagner SR, Greene FE (1978) Dieldrin-induced alterations in biogenic amine content of rat brain. Toxicol Appl Pharmacol 43(1):45–55
Walker FO (2007) Huntington’s disease. Lancet 369(9557):218–228
Watson RR, Killgore WD (2016) Nutrition and lifestyle in neurological autoimmune diseases: multiple sclerosis. Academic, Amsterdam
Wexler NS (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proc Natl Acad Sci 101(10):3498–3503
Wexler NS et al (1987) Homozygotes for Huntington’s disease. Nature 326(6109):194–197
Wingerchuk DM, Carter JL (2014) Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 89(2):225–240. Elsevier
World Health Organization (1980) International classification of impairments, disabilities, and handicaps: a manual of classification relating to the consequences of disease, published in accordance with resolution WHA29. 35 of the Twenty-ninth World Health Assembly, May 1976
Xiao W et al (2011) A genomic storm in critically injured humans. J Exp Med 208(13):2581–2590
Yoon BH et al (1997) Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1β, and tumor necrosis factor-α), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol 177(1):19–26
Zecca L et al (2002) The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson’s disease. FEBS Lett 510(3):216–220
Zheng W, Monnot AD (2012) Regulation of brain iron and copper homeostasis by brain barrier systems: implication in neurodegenerative diseases. Pharmacol Ther 133(2):177–188
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Rai, S.N. et al. (2019). Pathophysiology of the Disease Causing Physical Disability. In: Paul, S. (eds) Biomedical Engineering and its Applications in Healthcare. Springer, Singapore. https://doi.org/10.1007/978-981-13-3705-5_23
Download citation
DOI: https://doi.org/10.1007/978-981-13-3705-5_23
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-3704-8
Online ISBN: 978-981-13-3705-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)